Every Form 4 that Processa Pharmaceuticals, Inc. Common (PCSA) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow PCSA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PCSA filings page.
Processa Pharmaceuticals director Neal James R reported an open-market purchase of the company’s Common Stock. On March 31, 2026, he bought 789 shares at a price of $2.535 per share, bringing his direct ownership to 818 shares after the transaction, indicating a small, routine insider buy.
Processa Pharmaceuticals Pres. of Research & Development David Young bought 1,810 shares of common stock in an open-market purchase at $2.535 per share. After this trade, he directly holds 10,562 shares and has additional indirect holdings through the Young-Plaisance Revocable Trust, family entities, and CorLyst, LLC.
Processa Pharmaceuticals, Inc. Chief Financial Officer Russell Skibsted reported an open-market purchase of company stock. He bought 2,324 shares of Common Stock at a price of $2.535 per share on March 31, 2026, and now directly holds 2,324 shares following this transaction.
Processa Pharmaceuticals director Geraldine Pannu reported an open-market purchase of Common Stock. On March 31, 2026, she bought 2,072 shares at $2.535 per share, bringing her direct holdings to 2,188 shares. This was a straightforward open-market buy with no derivatives involved.
Processa Pharmaceuticals, Inc. Chief Executive Officer George K. Ng bought additional company stock. On March 31, 2026, he made an open-market purchase of 2,136 shares of Processa common stock at $2.535 per share.
Following this transaction, Ng directly holds 3,649 common shares. He also has indirect ownership of 3,488 shares through an account labeled "George Ng IRRA FOB George Ng" and 800 shares through the "Ng Cha Family Trust," giving him a larger combined economic stake in PCSA.
Processa Pharmaceuticals, Inc. Chief Business & Strategy Officer Patrick Lin made an open-market purchase of 1,603 shares of common stock at $2.535 per share. Following this transaction, he directly holds 3,356 shares. In addition, 1,740 shares are held indirectly through the Lin Family Trust dated February 4, 2024.
Processa Pharmaceuticals Chief Administrative Officer Wendy Guy bought shares in the company. On the open market, she purchased 1,854 shares of common stock at $2.535 per share, increasing her direct holdings to 3,110 shares. She also has indirect ownership of 333 shares held by CorLyst, LLC.
Processa Pharmaceuticals’ Chief Development Officer, Bigora Sian, purchased common stock in the open market. On March 31, 2026, Sian bought 2,107 shares of Processa Pharmaceuticals common stock at $2.535 per share, increasing direct ownership to 3,711 shares. The filing also reports indirect ownership of 267 shares held through CorLyst, LLC.
Processa Pharmaceuticals director Baluch Khoso bought shares of the company in the open market. On this transaction date, he purchased 2,269 shares of Common Stock at an average price of $2.535 per share in an open-market purchase. Following this trade, he directly owns 2,325 Processa Pharmaceuticals common shares.
Processa Pharmaceuticals director and officer David Young, President of Research & Development, reported the vesting and distribution of restricted stock units into common stock on January 1, 2026. A total of 49 restricted stock units were converted at an exercise price of $0, resulting in 49 common shares acquired.
Following this transaction, Young holds 8,752 Processa common shares directly. He also has indirect beneficial ownership of common stock, including 1,242 shares through the Young-Plaisance Revocable Trust, 432 shares through family entities, and 742 shares through CorLyst, LLC. The filing describes the event as a distribution of vested restricted shares.
Processa Pharmaceuticals Chief Business - Strategy Officer Patrick Lin reported a small equity transaction. On January 1, 2026, Lin acquired 193 shares of Common Stock at an exercise price of $0 through the conversion of a derivative security, described as a distribution of vested restricted shares.
Following this vesting-related transaction, Lin directly beneficially owned 1,753 shares of Common Stock. In addition, 1,740 shares were held indirectly through the Lin Family Trust Feb 4, 2024, reflecting his combined direct and indirect ownership position in Processa Pharmaceuticals.
Processa Pharmaceuticals, Inc. reported an equity award transaction by Chief Administrative Officer Wendy Guy. On January 1, 2026, 193 restricted stock units converted into 193 shares of common stock at a price of $0 per share, described as a distribution of vested restricted shares. Following the transaction, Guy beneficially owned 1,256 shares of common stock directly and 333 shares indirectly through CorLyst, LLC.
Processa Pharmaceuticals Chief Development Officer Sian Bigora reported an equity award vesting and related share distribution. On January 1, 2026, 249 restricted stock units converted into 249 shares of common stock at an exercise price of $0, described as a distribution of vested restricted shares.
Following this transaction, Bigora beneficially owns 1,604 shares of Processa common stock directly and an additional 267 shares indirectly through CorLyst, LLC. The filing reflects compensation-related share delivery rather than an open‑market purchase or sale.
Neal James R, a Director of Processa Pharmaceuticals, Inc. (PCSA), reported issuance of equity awards dated 10/01/2025. The Form 4 shows 100,000 Restricted Stock Units (RSUs) granted with a reported value of $0 and 300,000 stock options granted with a conversion/exercise price of $0.198. Following the reported transactions the reporting person beneficially owns 100,000 RSUs and 300,000 options, each held directly. The RSUs vest one-third on 10/01/2026 and then one-thirty-sixth monthly until fully vested on 10/01/2028. The options vest one-third on the first anniversary of the grant, with the remainder vesting ratably over the next two years. The Form 4 is signed by an attorney-in-fact on behalf of the reporting person and dated 10/03/2025.
Processa Pharmaceuticals, Inc. (PCSA) director Khoso Baluch reported receipt on 10/01/2025 of equity awards: 100,000 Restricted Stock Units and 300,000 stock options with an exercise price of $0.198. Following the grants, the reporting person beneficially owns 100,000 RSUs and 300,000 options directly.
The RSUs vest one-third on 10/01/2026 and then monthly over the following 24 months until fully vested on 10/01/2028. The stock options vest one-third on the first anniversary of the grant, with the remainder vesting ratably over the next two years. The Form 4 was signed by an attorney-in-fact on 10/03/2025.
Geraldine Pannu, a director of Processa Pharmaceuticals, Inc. (PCSA), reported grants on 10/01/2025 consisting of 100,000 restricted stock units (RSUs) and 300,000 stock options with an exercise price of $0.198. The RSUs vest one-third on 10/01/2026 and then monthly over two additional years until fully vested on 10/01/2028. The options vest one-third on the first anniversary of the grant with the remainder vesting ratably over the next two years. Following these grants, Ms. Pannu beneficially owns 100,000 shares represented by the RSUs and has rights to acquire 300,000 shares via options. The Form 4 was signed on 10/03/2025 by an attorney-in-fact on her behalf.
Processa Pharmaceuticals, Inc. (PCSA) reported a Form 4 showing that director Justin W. Yorke received equity awards dated 10/01/2025. The filing discloses 100,000 Restricted Stock Units (RSUs) and 300,000 stock options granted to Mr. Yorke. The RSUs vest one-third on 10/01/2026 and then monthly in one-thirty-sixths until fully vested on 10/01/2028. The options vest one-third on the first anniversary of the grant with the remainder vesting ratably over the following two years. Price terms shown are $0 for the RSUs and $0.198 exercise price for the options. The report was signed on 10/03/2025.
Wendy Guy, listed as Chief Administrative Officer and a director of Processa Pharmaceuticals, Inc. (PCSA), reported equity awards dated 10/01/2025. The Form 4 shows the grant of 50,000 Restricted Stock Units (RSUs) and 150,000 stock options with an exercise price of $0.198. Following the transactions, she beneficially owns 50,000 RSUs and 150,000 options directly.
The RSUs vest one-third on 10/01/2026 and then vest monthly (one‑thirty‑sixth) until fully vested on 10/01/2028. The stock options vest one‑third on the first anniversary of the grant and the remainder vests ratably over the following two years.
Processa Pharmaceuticals, Inc. (PCSA) reported insider awards to Patrick Lin, its Chief Business - Strategy Officer. On 10/01/2025 Mr. Lin was granted 68,000 Restricted Stock Units (RSUs) and 204,000 stock options with an exercise price of $0.198. The RSUs convert one-for-one to common shares and vest one-third on 10/01/2026 with the remainder vesting monthly through 10/01/2028. The options vest one-third on the first anniversary of the grant with the balance vesting ratably over the next two years. The Form 4 was signed via power of attorney on 10/03/2025.
Processa Pharmaceuticals, Inc. (PCSA) reported insider awards to Chief Development Officer Sian Bigora. On 10/01/2025 Ms. Bigora was granted 96,000 restricted stock units and 288,000 stock options with an exercise price of $0.198. The RSUs vest one-third on 10/01/2026 and then monthly over two years until fully vested on 10/01/2028. The options vest one-third on the first anniversary of the grant with the remainder vesting ratably over the next two years. Following the grants, Ms. Bigora beneficially owns 96,000 shares and 288,000 option shares, reported as direct ownership.
Processa Pharmaceuticals (PCSA) reported a Form 4 for its Chief Financial Officer, reflecting equity grants dated October 1, 2025. The filing shows an award of 108,000 Restricted Stock Units (RSUs) and stock options for 324,000 shares at an exercise price of $0.198 per share.
The RSUs vest one-third on October 1, 2026, then one-thirty-sixth each month until fully vested on October 1, 2028. The options vest one-third on the first anniversary of the grant date, with the remainder vesting ratably over the following two years. After these transactions, the filing lists 108,000 RSUs and 324,000 options beneficially owned, held directly.
David Young, President of Research & Development and a director at Processa Pharmaceuticals, Inc. (PCSA), reported equity awards granted on 10/01/2025. The filing shows 111,000 Restricted Stock Units granted, each converting to one share upon vesting: one-third vests on 10/01/2026 and the remainder vests monthly over two years until 10/01/2028. It also reports 333,000 stock options with an exercise price of $0.198; those options vest one-third on the first anniversary of the grant and the remainder ratably over the next two years. Following the transactions the reporting person beneficially owns the awarded 111,000 RSUs and 333,000 options. The Form is signed by an attorney-in-fact on 10/03/2025.
Processa Pharmaceuticals (PCSA) reported insider grants to CEO and director George Ng dated 10/01/2025. He was awarded 256,000 restricted stock units (RSUs) that vest one‑third on 10/01/2026 and then monthly over two years until fully vested on 10/01/2028. He also received 768,000 stock options with an exercise price of $0.198, vesting one‑third on the first anniversary and the remainder ratably over the next two years. Both awards are reported as directly owned following the grants. The Form 4 was signed on behalf of Mr. Ng by an attorney‑in‑fact and shows no dispositions or other securities changes.
Wendy Guy, identified as the reporting person and listed as Chief Administrative Officer, submitted an amended Form 4 for Processa Pharmaceuticals, Inc. (PCSA). The filing states a transaction date of 07/24/2025 and records a disposition of 26,339 shares of the issuer's common stock (transaction code V). After the reported transaction the filing shows beneficial ownership of 8,335 shares held indirectly through CorLyst, LLC.
The amendment expressly notes it was filed to retract a prior Form 4 that was filed in error. The amended Form 4 is signed via power of attorney on behalf of Wendy Guy by John J. Wolfel and dated 09/18/2025.
Processa Pharmaceuticals (PCSA) insider amendment: This amended Form 4, filed by Director Justin W. Yorke, corrects a prior filing submitted in error and reports changes in his holdings. The filing shows a disposition of 3,737 shares of common stock on 07/24/2025. After the reported transactions, Yorke beneficially owns 12,400 shares indirectly via a Directed Trust Company account for his IRA and 31,232 shares indirectly via Richland Fund, LLC. The amendment also reports warrants exercisable for common stock at a $0.65 price (expiring 01/29/2030) associated with the Directed Trust Company IRA: 12,400 and 6,200 underlying shares respectively. The form is signed by attorney-in-fact John J. Wolfel on behalf of Yorke.
Processa Pharmaceuticals, Inc. (PCSA) filed an amended Form 4 to correct an earlier filing. The amendment states the prior Form 4 was filed in error and retracts that prior report. The filing lists David Young (President, Research & Development and director) as the reporting person and shows a transaction date of 07/24/2025. The Table I entries indicate a disposition of 217,332 common shares and beneficial ownership reported as 30,985 shares direct plus indirect holdings: 10,786 shares via the Young-Plaisance Revocable Trust, 18,544 shares via CorLyst, LLC. The amendment is signed by David Young via attorney-in-fact John J. Wolfel on 09/18/2025.
Russell Skibsted, Chief Financial Officer of Processa Pharmaceuticals, Inc. (PCSA), amended a prior filing to report ownership of 28,000 restricted stock units. The RSUs convert to common stock and are structured to vest 50% on July 16, 2025, with the remaining 50% contingent on achievement of specified performance criteria. The amendment retracts an earlier Form 4 that was filed in error. The reported transaction date is July 24, 2025, and the amended Form 4 was signed by attorney-in-fact on September 18, 2025.
Geraldine Pannu, a director of Processa Pharmaceuticals, Inc. (PCSA), filed an amended Form 4 to correct prior reporting of her restricted stock and resulting direct beneficial ownership. The amendment discloses an acquisition code A for 31,206 shares of restricted stock acquired with a $0 price and underlying 31,206 shares of common stock. After the correction, Ms. Pannu directly beneficially owns 36,275 shares of common stock. The restricted shares are subject to vesting and will vest on the earlier of June 28, 2025 or the next annual meeting of stockholders, subject to certain distribution requirements. The filing states the amendment retracts a prior Form 4 that was filed in error and corrects the beneficially owned shares previously reported.
Processa Pharmaceuticals (PCSA) reporting person George K. Ng amended a prior Form 4 to correct an earlier filing error. The amendment shows Mr. Ng is both a director and the Chief Executive Officer. The filing discloses indirect beneficial ownership of 87,200 shares of common stock held through warrants and 20,000 shares held by the Ng Cha Family Trust, as well as separate warrant holdings converting into 87,200 and 43,600 common shares at a $0.65 exercise price expiring 01/29/2030. The earliest transaction date listed is 07/24/2025, and the amendment notes the prior Form 4 was filed in error.
Processa Pharmaceuticals, Inc. (PCSA) amended a prior Form 4 to correct reported insider holdings for reporting person Neal James R, who is identified as a director. The filing shows restricted stock granted with $0 price that vested subject to the earlier of June 28, 2025 or the next annual meeting, and records an acquisition of 31,206 restricted shares. The filing reports 36,275 common shares beneficially owned following the reported transactions. The amendment states it was filed to retract a prior Form 4 that was filed in error and to correct the beneficially owned shares previously reported on a Form 4 filed September 18, 2024. The form was signed by an attorney-in-fact on behalf of the reporting person.
Processa Pharmaceuticals insider amendment reports a corrected sale and existing family trust holdings. The filing amends a prior Form 4 to retract an earlier filing error and discloses a disposition of 38,727 shares of common stock reported as a sale. Following the reported transaction the reporting person is shown as beneficially owning 43,500 shares indirectly through the Lin Family Trust. The reporting person is an officer (Chief Business - Strategy Officer) and a director of the company. The amendment clarifies prior reporting and does not include derivative transactions or exercise details.
Form 4/A filed for Processa Pharmaceuticals, Inc. (PCSA) amends earlier reporting. The reporting person is Sian Bigora, identified as Chief Development Officer and Director. The earliest transaction date reported is 07/24/2025, with an amendment date of 07/28/2025 and a signature entry dated 09/18/2025. The filing shows a disposition of 33,626 shares of common stock and continued beneficial ownership of 6,668 shares held indirectly through CorLyst, LLC. The amendment states it was filed to retract a prior Form 4 that was filed in error. The document discloses insider role, the specific share disposition, and the indirect ownership vehicle.
Processa Pharmaceuticals director Khoso Baluch amended a prior Form 4 to correct reported insider holdings and retract an earlier erroneous filing. The amendment discloses a restricted stock grant of 31,206 shares that vest on the earlier of June 28, 2025 or the next annual meeting of stockholders, and states 36,275 shares as the amount of common stock beneficially owned following the reported transactions. The filing identifies the reporting person as a director and shows an earliest transaction date of 07/24/2025, an amendment date of 07/28/2025, and a signature date of 09/18/2025. The amendment states it was filed to correct the beneficially owned shares reported on a Form 4 filed September 18, 2024, and to retract that prior Form 4 which was filed in error.